The Role of Anticoagulation in COVID-19-Induced Hypercoagulability

Juan Simon Rico-Mesa, Daniel Rosas, Ashkan Ahmadian-Tehrani, Averi White, Allen S. Anderson, Robert Chilton

Research output: Contribution to journalReview articlepeer-review

70 Scopus citations


Purpose of Review: We aim to provide a comprehensive analysis of hypercoagulability in individuals affected by COVID-19. Our goal is to describe the hypercoagulable state related to the infection and provide guidance regarding the possible benefits of anti-coagulation with the support of evidence from current literature. Recent Findings: The incidence of thrombotic disease in individuals affected by COVID-19 is reported as high as 31%. A significant mortality benefit has been observed with the use of therapeutic anticoagulation in high-risk individuals. Literature supports the use of scoring systems, such as the sepsis-induced coagulopathy score, to risk-stratify individuals who might benefit from anticoagulation. Summary: COVID-19-induced hypercoagulability has been demonstrated to play a significant role in overall COVID-19 outcomes. Current literature shows promising evidence with the use of therapeutic anticoagulation in high-risk individuals. Further studies are needed to better analyze the risks and benefits of anticoagulation in this specific patient population.

Original languageEnglish (US)
Article number53
JournalCurrent Cardiology Reports
Issue number7
StatePublished - Jul 1 2020


  • Anticoagulation
  • COVID-19
  • Hypercoagulability
  • SARS-CoV-2

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'The Role of Anticoagulation in COVID-19-Induced Hypercoagulability'. Together they form a unique fingerprint.

Cite this